About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, formerly known as GPhA, works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products, and will educate the public and patients about the safety and effectiveness of biosimilars. Areas of focus will include education, access, the nascent regulatory environment, reimbursement and legal affairs. Member organizations include any company or stakeholder organization working to develop biosimilar products with the intent to compete in the U.S. market.
Please email email@example.com for more information.
Biosimilars Council Executive Director: Christine Simmon, AAM Senior Vice President, Policy & Strategic Alliances
2017 Biosimilars Council members:
Dr. Reddy’s Laboratories
Lupin Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc.
Teva Pharmaceuticals USA, Inc.
Zydus Pharmaceuticals USA, Inc.